NCT01987284

SER100 in Isolated Systolic Hypertension

A Randomized, Double-blind, Placebo-controlled, Cross-over, Multi-center Study Assessing the Safety, Tolerability and Efficacy of SER100 10 mg s.c. Twice Daily for 2 Days in Patients With Isolated Systolic Hypertension Insufficiently Treated With One or More Anti-hypertensives.

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 17 (actual)
• Sponsor: Serodus AS · Industry
• Sex: All
• Age: 50 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Isolated Systolic Hypertension (ISH)is the dominating hypertensive disease in elderly people. Much attention has recently been drawn to the strong relationship between the systolic blood pressure and cardiovascular morbidity. In previous clinical studies carried out in individuals with normal blood pressure at baseline SER100 decreased primarily the systolic blood pressure. It is hypothesized that the effect on systolic blood pressure in hypertensive patients will be larger or equal to the fall seen in normotensive patients.

Conditions

• Isolated Systolic Hypertension

Interventions

Type	Name	Description
DRUG	SER100
DRUG	Placebo

Timeline

• Start date: 2013-10-01
• Primary completion: 2014-07-01
• Completion: 2014-09-01
• First posted: 2013-11-19
• Last updated: 2016-10-20

Locations

7 sites across 4 countries: Finland, Hungary, Norway, United Kingdom